GHK-Cu Dosing: What Clinics Prescribe and What to Expect

Key Takeaways

• GHK-Cu is primarily available for research and not FDA-approved for clinical use.
• Typical dosing for GHK-Cu injections ranges from 1-2 mg, while topical formulations vary based on concentration.
• Titration schedules may commence with lower doses to assess tolerance and efficacy.
• Medical supervision is crucial due to the peptide's research-only status and potential side effects.

What Is GHK-Cu?

GHK-Cu, a tripeptide composed of Gly-His-Lys bound to copper(II) ions, plays a significant role in extracellular matrix modulation and cellular signaling. Despite its promising therapeutic potential, it remains in the research phase and is not FDA-approved for clinical applications. For more details, visit the GHK-Cu full profile.

Standard Dosing Protocols

Currently, GHK-Cu does not have an FDA-approved dosing protocol, as it is available only for research purposes. Published research suggests typical dosing for subcutaneous injections ranges from 1-2 mg per administration, depending on the study parameters (PMID 29986520). Topical applications, often used for cosmetic purposes, depend on product concentration but typically involve daily application (PMID 39963574).

Titration Schedules

In research settings, titration schedules for GHK-Cu injections often start with a lower dose to evaluate patient tolerance and efficacy. For example, a protocol might begin at 0.5 mg, increasing to 1 mg or more over several weeks. This gradual increase helps mitigate potential side effects and allows for individual response assessment.

Administration Method

GHK-Cu is administered via subcutaneous injection or topical application. For injections, common sites include the abdomen or thigh, using a 29-31 gauge needle. Proper storage in a refrigerator is essential to maintain peptide stability. Reconstitution involves mixing the peptide with bacteriostatic water, ensuring a concentration suitable for the prescribed dose.